Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes

NCT02462889 is registered in ClinicalTrials.gov with Jeffrey S Heier as lead sponsor.

NCT NCT02462889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02462889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes
Lead sponsor
Jeffrey S Heier
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
March 31, 2019
Enrollment
128 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration